Interview: Dr. Thomas Coffman – Dean, Duke-NUS Medical School, Singapore

27.09.2016
thomas-coffman-duke-nusDr. Thomas Coffman, Dean at Duke-NUS Medical School (Duke-NUS), explains how Duke-NUS has effectively disrupted medical education since the establishment of this unique collaboration 11 years ago. Can you introduce to our international readers the underlying aspirations behind the creation of this partnership between Duke University and NUS as well as the milestones since its foundation?
The Duke-NUS partnership has been focused on developing medical practitioners interested in research and innovation
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Research, R&D, Education, University, KOL, Singapore, Healthcare

Related Interviews

Ashish Mahajan – Partner, Deloitte Life Sciences & Healthcare…

Ashish Mahajan, Partner in Deloitte’s Life Sciences and Healthcare Consulting Practice in Southeast Asia, outlines some of the key trends playing out in the region, the extent to which the…

Subra Suresh – President, Nanyang Technological University (NTU),…

Professor Subra Suresh, president of Nanyang Technological University (NTU) and former director of the US National Science Foundation, explains how the university has managed to consistently be among the top…

Angeline Ho – Communication & Patient Advocacy Lead, Oncology Cell…

Angeline Ho gives an overview of the patient advocacy landscape in Asia-Pacific, why an Asian model of patient engagement – distinct from those in Europe and the US – needs…

Related Articles

Nordics / Danish-Swedish Clinical Trial Collaboration: Better Together?

Denmark boasts plenty of strong fundamentals as a clinical trials hub, but is perhaps constrained by a population of just 5.8 million and a correspondingly small patient pool. However, international…

Turkey / Can It Become a True Clinical Trials Hub?

Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global competitiveness. The government’s strategy is to increase…

Turkey / Solidarity: How COVID-19 Brought the Turkish R&D Ecosystem Together

As an upper-middle-income country with an emerging economy, Turkey could not invest billions in COVID-19 vaccine R&D, but a strong research ecosystem and willing industry allowed it to kickstart multiple…

Latest Report

InFigures Asia-Pacific 2021

Related Content

Research
R&D
Education
University
KOL
Singapore
Healthcare